A Prescription Drug User Fee Act target date of April 7, 2026 has been assigned to the application. The Food and Drug Administration (FDA) has granted Priority Review to enfortumab vedotin-ejfv ...

FDA approves pembrolizumab with chemotherapy for platinum-resistant ovarian cancer, showing significant survival benefits in ...

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — In this video, Susana M. Campos, MD, MPH, discusses results from a phase 2 trial of pembrolizumab and ...

BARCELONA, Spain — Adding pembrolizumab to standard concurrent chemoradiotherapy (CCRT) significantly improves overall survival in patients with high-risk, locally advanced cervical cancer, according ...

The benefit of the addition of perioperative pembrolizumab to standard care with surgery and adjuvant therapy for patients with locally advanced head and neck squamous-cell carcinoma (HNSCC) is ...

High TMB and TAM density may predict positive ICI response in DDLPS patients, as shown in a case with pembrolizumab achieving pCR. The patient, initially treated with doxorubicin, pazopanib, and ...

For patients with previously untreated, programmed death ligand 1 (PD-L1)-positive, locally advanced unresectable or metastatic triple-negative breast cancer (TNBC), sacituzumab govitecan plus ...

CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line treatment significantly reduced the risk of progression or death in ...